In fact, moesin has been found to be significantly upregulated in breast cancer, prostate cancer, pancreatic cancer, and other cancers [17, 22, 23], but there were few reports on changes the upregulation will cause in cancer. This evidence concerns the gene MSN and prostate carcinoma.